Lower Court Agrees With WuXi AppTec (And Many Of Us)

By Louis Garguilo, Chief Editor, Outsourced Pharma

One lower-court ruling does not make a victory. But it does add a little sanity to this melodrama.

On August 7, U.S. District Judge James Boasberg did something that has been surprisingly rare in the WuXi AppTec / BIOSECURE Act saga: He looked at the U.S. government's case for labeling WuXi a “Chinese military company” and decided the government had not shown enough evidence to allow the designation to continue while the underlying case is litigated.

The judge granted WuXi's request for a preliminary injunction, blocking the Department of Defense from enforcing the Section 1260H designation.

No, WuXi has not won the case. The BIOSECURE Act remains, as do larger questions regarding how the U.S. should protect its pharmaceutical supply chains from legitimate Chinese national-security risks.

But this is a consequential development. A court of law finally says, "Show us the evidence."

The Scarlet Letter

Judge Boasberg wrote that this "scarlet letter" sends a clear message to keep away. He's referring to what has happened to WuXi: some customers and suppliers have shifted business to competitors, or even ended long-standing relationships.

That is what I've been writing about since this saga began. Long before any actual prohibition takes effect, a government declaring a CDMO (as consequential as WuXi AppTec) a national-security danger will have far-reaching implications.

Sponsors cannot necessarily wait for the regulation to become enforceable. Pressures build quickly, and not just internally; board members and investors start to ask questions. The procurement organization must begin to look for alternatives.

And suddenly a company that has not been legally prohibited from doing business with a sponsor is being treated as if it has. That is exactly what Judge Boasberg appears to have recognized.

WuXi's Measured But Clear Response

Since the start of the BIOSECURE Act as proposed legislation in 2024, I've given WuXi plenty of space to make its case that it is in no way some kind of tool of the Chinese government.

This has been possible because while vehemently denying the accusations, WuXi’s responses have been professional in tone and measured in content.

Here is part of WuXi’s official response this time (dated August 9th, from Dr. Ge Li, Chairman, WuXi AppTec Co., Ltd.):

…Following the filing of our lawsuit against the DoD on June 11, 2026, we filed a motion for preliminary injunction with the U.S. District Court for the District of Columbia (the “Court”) on June 29, 2026 to seek enjoining the DoD from enforcing, implementing or taking any other action pursuant to the 1260H Designation. The Court held a hearing of our motion on July 22, 2026.

On August 7, 2026 (U.S. time), the Court issued a ruling on our motion for preliminary injunction. We welcome the Court’s decision to grant the preliminary injunction we petitioned for. This ruling relieves the Company from the immediate adverse consequences of the 1260H Designation during the judicial process challenging such designation. We continue to believe that the facts will prevail after an objective and fair judicial review …

The final italics are mine. Show us the evidence, produce any malfeasance that has been found to cause this designation as a threat to the U.S. biotech industry. Does the government have sufficient evidence to portray this CDMO as a part of the Chinese military (and thus government) apparatus?

Judge Boasberg has now stated (at this preliminary-injunction stage) that the government has not demonstrated that is the case.

Readers of Outsourced Pharma have shown great interest in this outsourcing story these past years – not in small part because many of you have contracted with and been pleased with the service and materials received from WuXi AppTec.

My BIOSECURE Act reporting now contains more than a dozen installments dating back to 2024. I've interviewed WuXi executives; editorially challenged the logic of the original legislation; openly questioned the use of implication and association as substitutes for evidence.

I've written about the damage the legislation was doing not to WuXi in isolation, but to our entire domestic and global outsourcing community.

None of this means I – or anyone – should take the side of this particular CDMO. Few of us are naïve about the challenges stemming from the Chinese Communist Party, or about China's well-documented tactics involving market access, forced business arrangements, intellectual-property theft and more.

A Teaching Moment

There is a serious lesson for our outsourcing community here.

Governments don’t have to shut down a CDMO to disrupt our entire outsourcing ecosystem. Biotechs and Pharma around the world have already had to reassess supply chain strategies and risk, with some scrambling for new or backup options. Some programs have been upended.

WuXi serves thousands of companies globally. The company told the court roughly 70% of its revenue came from U.S. customers last year. It employs about 450 people in the U.S., and has invested in impressive infrastructure here. 

I believe the U.S. should pursue legitimate national-security objectives, but should not resort to so casually dismantling highly productive pharmaceutical outsourcing relationships.

Let’s see how the U.S. government responds to this ruling. Let's see the evidence – if it exists.